Biography
Dr. Hany Elmariah is an Associate Professor in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University. Dr. Elmariah earned his MD and his MS in Biomedical Engineering at the University of Florida. He completed an Internal Medicine Residency at Duke University. Dr. Elmariah then completed a Hematology and Oncology Fellowship at Johns Hopkins University, where he also served as Chief Fellow. He then was a faculty member at the Moffitt Cancer Center before joining the faculty at Stanford University. Dr. Elmariah's clinical focus is allogeneic transplant for myeloid malignancies including acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. His research is focused on haploidentical and mismatched unrelated donor blood and marrow transplantation and novel cellular therapies for myeloid malignancies.
View Full Biography
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Medical Oncology (2018)
- Board Certification: American Board of Internal Medicine, Hematology (2018)
- Fellowship: Johns Hopkins Hematology and Medical Oncology Fellowship (2018) MD
-
- Board Certification: American Board of Internal Medicine, Internal Medicine (2014)
- Residency: Duke University Internal Medicine Residency (2014) NC
- Medical Education: University of Florida College of Medicine (2011) FL
Publications
-
Umbilical cord blood or HLA-haploidentical transplantation: Real world outcomes vs randomized trial outcomes.
O'Donnell, P. V., Brunstein, C. G., Fuchs, E. J., Zhang, M.-J. J., Allbee-Johnson, M., Antin, J. H., … Eapen, M. (2021). Umbilical cord blood or HLA-haploidentical transplantation: Real world outcomes vs randomized trial outcomes. Transplantation and Cellular Therapy. -
Early cytopenias and infections after standard of care idecabtagene vicleucel?in relapsed or refractory multiple myeloma.
Logue, J. M., Peres, L. C., Hashmi, H., Colin-Leitzinger, C., Shrewsbury, A. M., Hosoya, H., … Hansen, D. K. (2022). Early cytopenias and infections after standard of care idecabtagene vicleucel?in relapsed or refractory multiple myeloma. Blood Advances. -
MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
Brooks, E., Spahn, A., Waldvogel, S., Howard, A., Bar, M., Bratrude, B., … Bhatt, A. S. (2021). MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT. BLOOD. AMER SOC HEMATOLOGY. -
-
NCCN Guidelines Insights: Hematopoietic Cell Transplantation, Version 3.2022.
Saad, A., Loren, A., Bolanos-Meade, J., Chen, G., Couriel, D., Di Stasi, A., … Pluchino, L. A. (2023). NCCN Guidelines Insights: Hematopoietic Cell Transplantation, Version 3.2022. Journal of the National Comprehensive Cancer Network : JNCCN, 21(2), 108–115. -
Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
Holtan, S. G., Hamadani, M., Wu, J., Al Malki, M. M., Runaas, L., Elmariah, H., … Bolanos-Meade, J. (2022). Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703. BLOOD. AMER SOC HEMATOLOGY. -
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Bolaños-Meade, J., Hamadani, M., Wu, J., Al Malki, M. M., Martens, M. J., Runaas, L., … Holtan, S. G. (2023). Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. The New England Journal of Medicine, 388(25), 2338–2348. -
Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study
Kean, L., Siegel, S. J., Schmalz, J. T., Bien, S. A., Scheffey, D., Sanders, C., … DeWolf, S. (2023). Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study. BLOOD. AMER SOC HEMATOLOGY. -
Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation
Holtan, S. G., Martens, M. J., Al Malki, M. M., Efebera, Y., Kitko, C. L., Reshef, R., … Clark, W. (2023). Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation. BLOOD. AMER SOC HEMATOLOGY. -
LARGE-SCALE TCR DEEP SEQUENCING REVEALS A T CELL DIVERSITY BOTTLENECK WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH IMPLICATIONS FOR EFFICACY AND TOXICITY: RESULTS OF THE BMT-CTN 1801 STUDY
Kean, L., Siegel, S., Schmalz, J., Bien, S., DeWolf, S., Dong, J., … Perales, M.-A. (2024). LARGE-SCALE TCR DEEP SEQUENCING REVEALS A T CELL DIVERSITY BOTTLENECK WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH IMPLICATIONS FOR EFFICACY AND TOXICITY: RESULTS OF THE BMT-CTN 1801 STUDY. BONE MARROW TRANSPLANTATION. SPRINGERNATURE. -
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.
Holtan, S. G., Bolaños-Meade, J., Al Malki, M. M., Wu, J., Kitko, C. L., Reshef, R., … Martens, M. J. (2025). Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2400921. -
Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation
Handley, G., Yepes, A., Eliassen, E., Dominguez, G., Pasikhova, Y., Klinkova, O., … Faramand, R. (2024). Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation. OPEN FORUM INFECTIOUS DISEASES, 11(10), ofae564. -
Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis
Vazquez-Martinez, M. A., Caprice, T., Amisha, F., Almaraz, A., Kim, J., Cao, B., … Elmariah, H. (2024). Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis. BLOOD. ELSEVIER. -
Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia
Babu, A., Bower, K., Siraj, M., Cao, B., Kim, J., Elmariah, H., … Bejanyan, N. (2024). Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia. BLOOD. ELSEVIER. -
Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients
Adoncecchi, G., Kumar, A., Mogili, K., Faramand, R., Liu, H., Khimani, F., … Elmariah, H. (2025). Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients. CANCERS, 17(2). -
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results
Pidala, J., Holtan, S. G., Walton, K., Kim, J., Cao, B., Elmariah, H., … Betts, B. C. (2024). JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results. BLOOD, 144(22), 2295–2307. -
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Albanyan, O., Elmariah, H., Kalos, D., Kim, J., Faramand, R., Sallman, D., … Bejanyan, N. (2024). Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes. TRANSPLANTATION AND CELLULAR THERAPY, 30(11), 1090.e1–1090.e10. -
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide
Elmariah, H., Otoukesh, S., Kumar, A., Ali, H., Arslan, S., Dimaggio, E., … Al Malki, M. M. (2024). Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide. TRANSPLANTATION AND CELLULAR THERAPY, 30(10), 1019e1-1019e9. -
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
Jain, T., Estrada-Merly, N., Salas, M. Q., Kim, S., Devos, J., Chen, M., … Gupta, V. (2024). Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study. BLOOD ADVANCES, 8(16), 4281–4293. -
Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant
Ionescu, F., David, J. C., Ravichandran, A., Sallman, D. A., Sweet, K., Komrokji, R. S., … Lancet, J. E. (2024). Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 24(6), 400–406. -
Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations
Caprice, T., Fan, W., Kim, J., Faramand, R., Mishra, A., Perez, L., … Elmariah, H. (2024). Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations. AMERICAN JOURNAL OF HEMATOLOGY, 99(6), 1196–1200. -
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration
Jain, T., Tsai, H.-L., Elmariah, H., Vachhani, P., Karantanos, T., Wall, S. A., … Otoukesh, S. (2023). Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration. HAEMATOLOGICA, 108(12), 3321–3332. -
Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide
Elmariah, H., Otoukesh, S., Kumar, A., Ali, H., Arslan, S., Shouse, G., … Malki, M. M. A. (2024). Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. TRANSPLANTATION AND CELLULAR THERAPY, 30(2), e1–e11. -
A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Saha, A., Mohty, R., Whiting, J., Flores, K., Kim, J., Nishihori, T., … Lazaryan, A. (2023). A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma. BLOOD. ELSEVIER. -
Association between <i>CYP3A4</i>, <i>CYP3A5</i> and <i>ABCB1</i> genotype and tacrolimus treatment outcomes among allogeneic HSCT patients
Ho, T. T., Perkins, J. B., Gonzalez, R., Hicks, J. K., Martinez, R. A., Duranceau, K., … Elmariah, H. (2024). Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients. PHARMACOGENOMICS, 25(1), 29–40. -
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
Lee, D. H., Kumar, A., Mohammed, T., Peres, L. C., Alsina, M., Bachmeier, C., … Hansen, D. K. (2023). Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. BLOOD ADVANCES, 7(16), 4247–4257. -
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies
Saygin, C., Roloff, G., Hahn, C. N., Chhetri, R., Gill, S., Elmariah, H., … Godley, L. A. (2023). Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. BLOOD ADVANCES, 7(4), 549–554. -
Trends and in-hospital cardiac complications in patients with atrial fibrillation undergoing allogeneic stem cell transplant: A National Inpatient Sample analysis (2002-2019)
Din, M. A. U., Chowdhury, M., Shahzad, M., Zahid, S., Liaqat, H., Osama, M., & Elmariah, H. (2023). Trends and in-hospital cardiac complications in patients with atrial fibrillation undergoing allogeneic stem cell transplant: A National Inpatient Sample analysis (2002-2019). EUROPEAN JOURNAL OF HAEMATOLOGY, 110(6), 754–761. -
Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration.
Jain, T., Tsai, H.-L., Elmariah, H., Vachhani, P., Karantanos, T., Wall, S., … Otoukesh, S. (2023). Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration. Research Square. -
Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
Elmariah, H., Otoukesh, S., Kumar, A., Ali, H., Arslan, S., Desai, A., … Al Malki, M. M. (2022). Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide. BLOOD. ELSEVIER. -
Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Sallman, D. A., Elmariah, H., Sweet, K., Mishra, A., Cox, C. A., Chakaith, M., … Bejanyan, N. (2022). Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes. BLOOD. ELSEVIER. -
Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers
Jain, T., Tsai, H.-L., Elmariah, H., Vachhani, P., Karantanos, T., Wall, S. A., … Otoukesh, S. (2022). Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers. BLOOD. ELSEVIER. -
Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
Ionescu, F., Ajayi, E., Leach, A., Alsina, M., Bejanyan, N., Castaneda-Puglianini, O., … Faramand, R. (2022). Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience. BLOOD. ELSEVIER. -
Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience
Ionescu, F., Sallman, D. A., Sweet, K., Komrokji, R. S., Chan, O., Kuykendall, A., … Lancet, J. E. (2022). Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience. BLOOD. ELSEVIER. -
Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
Elmariah, H., Kim, J., Reid, K. M., Cubitt, C., Kuykendall, A., Lancet, J. E., … DeZern, A. E. (2022). Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML). BLOOD. ELSEVIER. -
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis
Wood, A. C., Perez, A. P., Arciola, B., Patel, K., Johnson, G., DiMaggio, E., … Jain, M. D. (2022). Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. TRANSPLANTATION AND CELLULAR THERAPY, 28(12), 829.e1–829.e8. -
Association between CYP3A4, CYP3A5, and ABCB1 Genotype, Tacrolimus Concentrations, and Outcomes Among Allogeneic Hematopoietic Stem Cell Transplantation Patients
Ho, T., Perkins, J., Gonzalez, R., Hicks, J. K., Nishihori, T., Bejanyan, N., … Elmariah, H. (2021). Association between CYP3A4, CYP3A5, and ABCB1 Genotype, Tacrolimus Concentrations, and Outcomes Among Allogeneic Hematopoietic Stem Cell Transplantation Patients. BLOOD. ELSEVIER. -
Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Sallman, D. A., Elmariah, H., Sweet, K., Talati, C., Mishra, A., Cox, C. A., … Bejanyan, N. (2021). Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes. BLOOD. ELSEVIER. -
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis
Jain, T., Tsai, H.-L., DeZern, A. E., Gondek, L. P., Elmariah, H., Bolanos-Meade, J., … Jones, R. J. (2022). Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. TRANSPLANTATION AND CELLULAR THERAPY, 28(5), 259.e1–259.e11. -
Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide
Otoukesh, S., Elmariah, H., Yang, D., Clark, M. C., Siraj, M., Ali, H., … Bejanyan, N. (2022). Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. TRANSPLANTATION AND CELLULAR THERAPY, 28(2), 111.e1–111.e8. -
Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation
Mirza, A.-S., Tandon, A., Jenneman, D., Cao, S., Brimer, T., Kumar, A., … Elmariah, H. (2022). Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. TRANSPLANTATION AND CELLULAR THERAPY, 28(4), 185.e1–185.e7. -
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease
Lazaryan, A., Lee, S., Arora, M., Kim, J., Betts, B. C., Khimani, F., … Pidala, J. A. (2022). A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. BLOOD ADVANCES, 6(1), 259–269. -
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study
Kunte, S., Rybicki, L., Viswabandya, A., Tamari, R., Bashey, A., Keyzner, A., … Jain, T. (2022). Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. LEUKEMIA, 36(3), 856–864. -
Increased Infections and Delayed CD4<SUP>+</SUP> T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation
Khimani, F., Ranspach, P., Elmariah, H., Kim, J., Whiting, J., Nishihori, T., … Bejanyan, N. (2021). Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. TRANSPLANTATION AND CELLULAR THERAPY, 27(11), 940–948. -
Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis
Khimani, F., Dutta, M., Faramand, R., Nishihori, T., Perez, A. P., Dean, E., … Mhaskar, R. (2021). Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. TRANSPLANTATION AND CELLULAR THERAPY, 27(7), 620.e1–620.e9. -
Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Pidala, J., Walton, K., Elmariah, H., Kim, J., Mishra, A., Bejanyan, N., … Betts, B. C. (2021). Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. CLINICAL CANCER RESEARCH, 27(10), 2712–2722. -
ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
Hansen, D. K., Kim, J., Thompson, Z., Hussaini, M., Nishihori, T., Ahmad, A., … Bejanyan, N. (2021). ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. TRANSPLANTATION AND CELLULAR THERAPY, 27(3), 256.e1–256.e7. -
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors
Grunwald, M. R., Zhang, M.-J., Elmariah, H., Johnson, M. H., St Martin, A., Bashey, A., … Eapen, M. (2021). Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. BLOOD ADVANCES, 5(4), 975–983. -
Impact of infused CD34+stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide
Hany, E., Naqvi, S. M. H., Kim, J., Nishihori, T., Mishra, A., Perez, L., … Bejanyan, N. (2021). Impact of infused CD34+stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. BONE MARROW TRANSPLANTATION, 56(7), 1683–1690. -
Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation
Elmariah, H., Brunstein, C. G., & Bejanyan, N. (2021). Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation. LIFE-BASEL, 11(2). -
A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation
Bejanyan, N., Pidala, J. A., Wang, X., Thapa, R., Nishihori, T., Elmariah, H., … Ayala, E. (2021). A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. BLOOD ADVANCES, 5(5), 1154–1163. -
Fludarabine-melphalan Conditioning Results in Favorable leukemia-free Survival after Allogeneic Transplantation in Patients with Active or Measurable Residual AML
Bower, K., Siraj, M., Kim, J., Cao, B., Elmariah, H., Perez, L., … Bejanyan, N. (2020). Fludarabine-melphalan Conditioning Results in Favorable leukemia-free Survival after Allogeneic Transplantation in Patients with Active or Measurable Residual AML. BONE MARROW TRANSPLANTATION. SPRINGERNATURE. -
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
Kirtane, K., Elmariah, H., Chung, C. H., & Abate-Daga, D. (2021). Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 9(7). -
Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide
DeZern, A. E., Elmariah, H., Zahurak, M., Rosner, G. L., Gladstone, D. E., Ali, S. A., … Jones, R. J. (2020). Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(11), 2075–2081. -
Impact of <i>TP53</i> gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
Chan, O., Hunter, A., Talati, C., Sallman, D. A., Asghari, H., Song, J., … Mishra, A. (2019). Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation. BLOOD. AMER SOC HEMATOLOGY. -
Delayed CD4+T-Cell but Faster B-Cell Immune Reconstitution after Ptcy-Based Compared to Conventional Gvhd Prophylaxis after Allogeneic Transplantation
Ranspach, P., Zhou, J.-M., Pidala, J. A., Nishihori, T., Nieder, M. L., Elmariah, H., … Khimani, F. (2020). Delayed CD4+T-Cell but Faster B-Cell Immune Reconstitution after Ptcy-Based Compared to Conventional Gvhd Prophylaxis after Allogeneic Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC. -
Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor
Grunwald, M. R., Zhang, M.-J., Elmariah, H., Johnson, M. H., St Martin, A., Bashey, A., … Eapen, M. (2019). Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor. BLOOD. AMER SOC HEMATOLOGY. -
Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
Chan, O., Talati, C., Asghari, H., Bejanyan, N., Elmariah, H., Hussaini, M., … Mishra, A. (2019). Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome. BLOOD. AMER SOC HEMATOLOGY. -
Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant
Mirza, S., Tandon, A., Jenneman, D., Cao, S., Kumar, A., Kidd, M. R., … Elmariah, H. (2019). Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant. BLOOD. AMER SOC HEMATOLOGY. -
Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Review and Meta-Analysis
Dutta, M., Mhaskar, R., Elmariah, H., Nishihori, T., Shah, B., Nieder, M., … Khimani, F. (2019). Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Review and Meta-Analysis. BLOOD. AMER SOC HEMATOLOGY. -
Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience
Hashmi, H., Lancet, J., Mishra, A., Sweet, K. L., Komrokji, R. S., Fernandez, H. F., … Nishihori, T. (2019). Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience. BLOOD. AMER SOC HEMATOLOGY. -
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes
Balaji, A., Zhang, J., Wills, B., Marrone, K. A., Elmariah, H., Yarchoan, M., … Naidoo, J. (2019). Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. JOURNAL OF ONCOLOGY PRACTICE, 15(9), 494-+. -
Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results
Elmariah, H., & Fuchs, E. J. (2019). Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results. SEMINARS IN HEMATOLOGY, 56(3), 183–189. -
Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment
Elmariah, H., & DeZern, A. E. (2019). Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 14(3), 154–163. -
Survival of Older Patients with AML andMDS after Allogeneic Hematopoietic Transplantation Is Best Determined By Combining Disease Risk and Comorbidity Indices
Asghari, H., Mo, Q., Naqvi, S. M., Lazaryan, A., Davila, M. L., Nishihori, T., … Bejanyan, N. (2019). Survival of Older Patients with AML andMDS after Allogeneic Hematopoietic Transplantation Is Best Determined By Combining Disease Risk and Comorbidity Indices. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC. -
Immune-related adverse events requiring inpatient management: Spectrum of toxicity, treatment, and outcomes.
Balaji, A., Zhang, J., Marrone, K., Elmariah, H., Yarchoan, M., Holdhoff, M., … Naidoo, J. (2018). Immune-related adverse events requiring inpatient management: Spectrum of toxicity, treatment, and outcomes. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Pan-pseudothrombocytopenia: An unusual case of platelet clumping
Elmariah, H., & Shanbhag, S. (2018). Pan-pseudothrombocytopenia: An unusual case of platelet clumping. AMERICAN JOURNAL OF HEMATOLOGY, 93(8), 1113–1114. -
Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors
Elmariah, H., Kasamon, Y. L., Zahurak, M., Macfarlane, K. W., Tucker, N., Rosner, G. L., … Ambinder, R. F. (2018). Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(5), 1099–1102. -
Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia
Elmariah, H., & Pratz, K. W. (2017). Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(7), 959–966. -
The Burden of Burnout: An Assessment of Burnout Among Internal Medicine Residents After the 2011 Duty Hour Changes
Elmariah, H., Thomas, S., Boggan, J. C., Zaas, A., & Bae, J. (2017). The Burden of Burnout: An Assessment of Burnout Among Internal Medicine Residents After the 2011 Duty Hour Changes. AMERICAN JOURNAL OF MEDICAL QUALITY, 32(2), 156–162. -
Genes Associated with Survival in Adult Sickle Cell Disease
Elmariah, H., Garrett, M. E., Soldano, K. L., Ataga, K. I., Eckman, J. R., Telen, M. J., & Ashley-Koch, A. E. (2014). Genes Associated with Survival in Adult Sickle Cell Disease. BLOOD. AMER SOC HEMATOLOGY. -
Inferior Vena Cava Filters in Trauma Patients: A National Practice Patterns Survey of US Trauma Centers
Rajasekhar, A., Elmariah, H., Lottenberg, L., Beyth, R., Lottenberg, R., & Ang, D. (2014). Inferior Vena Cava Filters in Trauma Patients: A National Practice Patterns Survey of US Trauma Centers. AMERICAN SURGEON, 80(12), 1237–1244. -
Factors associated with survival in a contemporary adult sickle cell disease cohort
Elmariah, H., Garrett, M. E., De Castro, L. M., Jonassaint, J. C., Ataga, K. I., Eckman, J. R., … Telen, M. J. (2014). Factors associated with survival in a contemporary adult sickle cell disease cohort. AMERICAN JOURNAL OF HEMATOLOGY, 89(5), 530–535. -
Inferior Vena Cava Filters in Trauma Patients: A National Practice Pattern Survey of US Trauma Centers
Rajasekhar, A., Elmariah, H., Ang, D., Lottenberg, L., Beyth, R., & Lottenberg, R. (2012). Inferior Vena Cava Filters in Trauma Patients: A National Practice Pattern Survey of US Trauma Centers. BLOOD. AMER SOC HEMATOLOGY. -
Commentary: Target CD34 Cell Dose for Allogeneic Hematopoietic Cell Transplantation: Can We Finally Agree?
Elmariah, H. (2022). Commentary: Target CD34 Cell Dose for Allogeneic Hematopoietic Cell Transplantation: Can We Finally Agree? Transplantation and Cellular Therapy, 28(2), 59–60. -
Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.
Siegel, S. J., DeWolf, S., Schmalz, J., Saber, W., Dong, J., Martens, M. J., … Kean, L. S. (2025). Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant. MedRxiv : the Preprint Server for Health Sciences. -
Accurate prediction of absolute prokaryotic abundance from DNA concentration.
Wirbel, J., Andermann, T. M., Brooks, E. F., Evans, L., Groth, A., Dvorak, M., … Bhatt, A. S. (2025). Accurate prediction of absolute prokaryotic abundance from DNA concentration. Cell Reports Methods, 101030. -
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703.
Abedin, S. M., Martens, M. J., Bolaños-Meade, J., Al Malki, M. M., Lian, Q., Runaas, L., … Hamadani, M. (2025). Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703. Blood Advances. -
Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
Abedin, S., Lian, Q., Martens, M. J., Malki, M. M. A., Elmariah, H., Gooptu, M., … Hamadani, M. (2024). Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis. BLOOD. ELSEVIER. -
Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
Elmariah, H., Kim, J., Reid, K., Cubitt, C., Kuykendall, A. T., Lancet, J. E., … Dezern, A. E. (2024). Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML). BLOOD. ELSEVIER. -
Optimal GVHD Prophylaxis.
Elmariah, H., & Bolaños-Meade, J. (2025). Optimal GVHD Prophylaxis. Advances in Experimental Medicine and Biology, 1475, 77–102. -
Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning With Haploidentical Donor Peripheral Blood Stem Cell Transplant.
Elmariah, H., Kim, J., Gonzalez, R., DiMaggio, E., Sansil, S., Mishra, A., … Bejanyan, N. (2025). Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning With Haploidentical Donor Peripheral Blood Stem Cell Transplant. American Journal of Hematology. -
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.
Schmitz, J., Gaskill, E., Price, S., Cao, B., Kim, J., Baluch, A., … Elmariah, H. (2025). Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide. Bone Marrow Transplantation. -
Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML.
Salhotra, A., Bejanyan, N., Yang, D., Mokhtari, S., Knobler, D., Park, G., … Nakamura, R. (2025). Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML. Transplantation and Cellular Therapy. -
Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia.
Gaskill, E., Albanyan, O., Naqvi, S. M., Mo, Q., Belfon, A., Nishihori, T., … Elmariah, H. (2025). Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia. Transplantation and Cellular Therapy. -
Hematopoietic Cell Transplantation, Version 3.2025
Loren, A. W., Mielcarek, M., Bolanos-Meade, J., Brammer, J., Cowden, M., Di Stasi, A., … Stehman, K. (2025). Hematopoietic Cell Transplantation, Version 3.2025. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 23(10). -
Reducing Effects of Hospital Associated Deconditioning in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation-
Schmitz, J., Weigl, B., Patterson, A., Kumar, A., Johansson, M., & Elmariah, H. (2025). Reducing Effects of Hospital Associated Deconditioning in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation-. CLINICAL JOURNAL OF ONCOLOGY NURSING, 29(5), 416–422. -
Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.
Sallman, D. A., McLemore, A. F., Komrokji, R. S., Elmariah, H., Kuykendall, A. T., Bejanyan, N., … Mishra, A. (2025). Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes. Blood Advances. -
Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., … Smith, M. (2025). Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL. BLOOD. ELSEVIER. -
Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study
Siegel, S., Dewolf, S., Schmalz, J., Winn, N., Kaminski, J., Bien, S., … Kean, L. (2025). Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study. BLOOD. ELSEVIER. -
Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT
Jeyakumar, N., Torres, N., Godbole, S., Yamamoto, F., Zhang, B., Arai, S., … Kennedy, V. (2025). Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT. BLOOD. ELSEVIER. -
Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation
Molina, A., Bubb, Q., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., … Kennedy, V. (2025). Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation. BLOOD. ELSEVIER. -
Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study
Omdahl, K. I., Siegel, S., Dong, J., Dewolf, S., Hebert, K., Neuberg, D., … Kean, L. (2025). Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study. BLOOD. ELSEVIER. -
Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data
Kongtim, P., Portuguese, A., Kim, S., Peterson, A., Elmariah, H., Muffly, L., … Scott, B. (2025). Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data. BLOOD. ELSEVIER. -
Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy
Wagstaff, C., Mishra, A., McLemore, A., Chan, O., Shallis, R., Pidala, J., … Sallman, D. (2025). Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy. BLOOD. ELSEVIER. -
Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.
Aguirre, L. E., Kim, H. T., Elmariah, H., Frumm, S. M., Kelkar, A. H., Ho, V. T., … Stahl, M. F. (2026). Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation. Blood Advances. -
Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes.
Sallman, D. A., McLemore, A. F., Komrokji, R., Elmariah, H., Kuykendall, A. T., Bejanyan, N., … Mishra, A. (2026). Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes. Blood Advances, 10(4), 1053–1057. -
Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study.
Wirbel, J., Saber, W., Martens, M. J., Peled, J. U., Andermann, T. M., Fei, T., … Bhatt, A. S. (2026). Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study. BioRxiv : the Preprint Server for Biology. -
Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy
Kennedy, V. E., Lauer, M., Shiraz, P., Arai, S., Johnston, L., Bharadwaj, S., … On, S. (2026). Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC. -
Effect of GVHD Prophylaxis on Renal Function and Survival Outcomes in Allogeneic Hematopoietic Cell Transplant Patients with Pre-Existing Renal Impairment
Amisha, F., Schmitz, J., Vazquez-Martinez, M., Caprice, T., Kim, J., Naqvi, S. M., … Bejanyan, N. (2026). Effect of GVHD Prophylaxis on Renal Function and Survival Outcomes in Allogeneic Hematopoietic Cell Transplant Patients with Pre-Existing Renal Impairment. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC. -
Patient Characteristics, Toxicity, and Response after Real World Administration of Obecabtagene Autoleucel and Brexucabtagene Autoleucel for Relapsed Acute Lymphoblastic Leukemia: A Rocca Analysis
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., … Muffly, L. S. (2026). Patient Characteristics, Toxicity, and Response after Real World Administration of Obecabtagene Autoleucel and Brexucabtagene Autoleucel for Relapsed Acute Lymphoblastic Leukemia: A Rocca Analysis. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC. -
Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.
Molina, A., Bubb, Q. R., Srinagesh, H. K., Yee, R., Arai, S., Bharadwaj, S., … Kennedy, V. (2026). Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. -
Superior Long-Term Survival with Fludarabine-Melphalan RIC Regimen in Older AML/MDS Patients: A Propensity Score Analysis of CIBMTR Data
Kongtim, P., Portuguese, A. J., Soyoung, K., Peterson, A., Elmariah, H., Muffly, L. S., … Scott, B. (2026). Superior Long-Term Survival with Fludarabine-Melphalan RIC Regimen in Older AML/MDS Patients: A Propensity Score Analysis of CIBMTR Data. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC.
-
NCCN Guidelines Insights: Hematopoietic Cell Transplantation, Version 3.2022.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
SHC- Oncology Palo Alto, CA
Palo Alto, CAImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records